Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-22-3291
Abstract: Radiopharmaceutical therapy is changing the standard of care in prostate cancer (PCa) and other malignancies. We previously reported high CD46 expression in PCa and developed an antibody-drug conjugate and immunoPET agent based on the YS5… read more here.
Keywords: prostate cancer; pca; cd46; cd46 targeted ... See more keywords